Free Trial
NASDAQ:AMPH

Amphastar Pharmaceuticals (AMPH) Stock Price, News & Analysis

Amphastar Pharmaceuticals logo
$30.62 +0.36 (+1.19%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$30.64 +0.02 (+0.08%)
As of 08/29/2025 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Amphastar Pharmaceuticals Stock (NASDAQ:AMPH)

Key Stats

Today's Range
$30.18
$30.81
50-Day Range
$20.62
$30.62
52-Week Range
$20.39
$53.96
Volume
290,925 shs
Average Volume
638,844 shs
Market Capitalization
$1.42 billion
P/E Ratio
11.47
Dividend Yield
N/A
Price Target
$31.60
Consensus Rating
Hold

Company Overview

Amphastar Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

AMPH MarketRank™: 

Amphastar Pharmaceuticals scored higher than 66% of companies evaluated by MarketBeat, and ranked 333rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Amphastar Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Amphastar Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Amphastar Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Amphastar Pharmaceuticals are expected to decrease by -5.73% in the coming year, from $3.49 to $3.29 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Amphastar Pharmaceuticals is 11.47, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 268.93.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Amphastar Pharmaceuticals is 11.47, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.11.

  • Price to Book Value per Share Ratio

    Amphastar Pharmaceuticals has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Amphastar Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    11.79% of the float of Amphastar Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Amphastar Pharmaceuticals has a short interest ratio ("days to cover") of 7.6.
  • Change versus previous month

    Short interest in Amphastar Pharmaceuticals has recently increased by 0.25%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Amphastar Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Amphastar Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.79% of the float of Amphastar Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Amphastar Pharmaceuticals has a short interest ratio ("days to cover") of 7.6.
  • Change versus previous month

    Short interest in Amphastar Pharmaceuticals has recently increased by 0.25%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Amphastar Pharmaceuticals has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.05 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Amphastar Pharmaceuticals this week, compared to 5 articles on an average week.
  • Search Interest

    Only 2 people have searched for AMPH on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Amphastar Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,985.00 in company stock.

  • Percentage Held by Insiders

    27.50% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    65.09% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Amphastar Pharmaceuticals' insider trading history.
Receive AMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AMPH Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.tc pixel
See More Headlines

AMPH Stock Analysis - Frequently Asked Questions

Amphastar Pharmaceuticals' stock was trading at $37.13 on January 1st, 2025. Since then, AMPH stock has decreased by 17.5% and is now trading at $30.62.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) released its quarterly earnings data on Monday, November, 8th. The company reported $0.46 EPS for the quarter, beating analysts' consensus estimates of $0.24 by $0.22. The company had revenue of $112.20 million for the quarter, compared to analysts' expectations of $103 million. Amphastar Pharmaceuticals had a net margin of 18.64% and a trailing twelve-month return on equity of 20.76%.
Read the conference call transcript
.

Amphastar Pharmaceuticals' top institutional shareholders include TD Asset Management Inc (4.32%), Epoch Investment Partners Inc. (2.67%), Boston Trust Walden Corp (2.50%) and Geode Capital Management LLC (2.06%). Insiders that own company stock include Mary Z Luo, Howard Lee, Rong Zhou, William J Peters, Floyd F Petersen, Yakob Liawatidewi, Richard K Prins and Michael A Zasloff.
View institutional ownership trends
.

Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amphastar Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), ServiceNow (NOW), Novo Nordisk A/S (NVO) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
11/08/2021
Today
8/30/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - GENERIC DRG
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AMPH
CIK
1297184
Employees
2,028
Year Founded
N/A

Price Target and Rating

High Price Target
$36.00
Low Price Target
$25.00
Potential Upside/Downside
+3.2%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$2.67
Trailing P/E Ratio
11.47
Forward P/E Ratio
8.77
P/E Growth
N/A
Net Income
$159.52 million
Net Margins
18.64%
Pretax Margin
22.40%
Return on Equity
20.76%
Return on Assets
9.68%

Debt

Debt-to-Equity Ratio
0.80
Current Ratio
3.29
Quick Ratio
2.21

Sales & Book Value

Annual Sales
$731.97 million
Price / Sales
1.94
Cash Flow
$5.06 per share
Price / Cash Flow
6.05
Book Value
$16.29 per share
Price / Book
1.88

Miscellaneous

Outstanding Shares
46,490,000
Free Float
33,709,000
Market Cap
$1.42 billion
Optionable
Optionable
Beta
0.76

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:AMPH) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners